Basket | Login


Science watch


Our science watch section reports on the story behind the media-reported “breakthrough” headlines in dementia, by focusing on the original journal study. Reports of other developments in research on care and cure are also included.

13/04/2021 Otzuka and Lundbeck continue Phase III trial with brexpiprazole in people with dementia, following an independent interim analysis
12/04/2021 CPAD consortium announces the expansion of its Alzheimer's disease data repository
07/04/2021 Impairment of hearing and sight can increase the risk of dementia, study finds
05/04/2021 The FDA rejects the application for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis
01/04/2021 Study shows that cholinesterase inhibitors have a modest, but long-lasting effect on cognitive decline in Alzheimer's dementia
01/04/2021 Study shows that blood biomarkers can accurately predict the presence of Alzheimer's disease pathology in the brain
31/03/2021 Independent Data Safety Monitoring Board recommends the continuation of Phase IIb/III trial of Anavex for AD
24/03/2021 New study shows improvement in cognition after sargramostim treatment
24/03/2021 Alzheimer's Research UK announces three-year partnership with Boston University Alzheimer's Disease Center
13/03/2021 Phase 2 trial results show a reduction in clinical decline for participants receiving donanemab
08/03/2021 Acadia Pharmaceuticals provides regulatory update on its drug application for pimavanserin
03/03/2021 Laboratory study shows how ApoE4 disrupts the lipid composition of brain cells in AD
01/03/2021 Researchers develop a new molecule that may reduce the amyloid plaques in mouse models
01/03/2021 Preclinical study shows improvement in cognitive function after cannabidiol treatment in a model of Alzheimer's disease
01/03/2021 Analyses in AD mouse models identify links between the gut microbiome, epigenetics and cognitive performance